Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
South Korea · Delayed Price · Currency is KRW 6,340.00
0.00 (0.00%)
At close: Sep 4, 2026
Kwang Dong Pharmaceutical Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,707,288 | 1,659,512 | 1,640,719 | 1,514,454 | 1,431,545 | 1,338,182 |
Revenue Growth | 5.50% | 1.15% | 8.34% | 5.79% | 6.98% | 7.59% |
Gross Profit Gross Profit Growth | 311,624 | 298,955 | 296,982 | 297,891 | 279,995 | 272,312 |
Operating Income Operating Income Growth | 33,540 | 31,046 | 30,097 | 42,070 | 38,244 | 44,936 |
Net Income Net Income Growth | 21,823 | 20,968 | 40,481 | 36,966 | 24,174 | 24,019 |
Earnings Per Share EPS Growth | 478.54 | 521.09 | 1011.00 | 913.00 | 588.00 | 584.33 |
EPS Growth | -30.25% | -48.46% | 10.73% | 55.27% | 0.63% | -47.78% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 177,703 | 227,690 | 165,450 | 206,181 | 208,632 | 187,701 |
Total Debt Total Debt Growth | 300,928 | 303,208 | 285,921 | 235,641 | 138,006 | 132,046 |
Net Cash (Debt) Net Cash Growth | -123,225 | -75,518 | -120,471 | -29,460 | 70,627 | 55,655 |
Net Cash Growth | - | - | - | - | 26.90% | 40.66% |
Net Cash Per Share Net Cash Per Share Growth | -2702.13 | -1876.71 | -3008.73 | -727.94 | 1719.22 | 1353.21 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 17,686 | 82,341 | -12,153 | -11,730 | 62,822 | 54,940 |
Capital Expenditures CapEx Growth | -16,664 | -29,862 | -75,730 | -34,785 | -25,383 | -23,795 |
Free Cash Flow Free Cash Flow Growth | 1,022 | 52,479 | -87,883 | -46,515 | 37,439 | 31,145 |
Free Cash Flow Growth | - | - | - | - | 20.21% | 77.30% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 18.25% | 18.02% | 18.10% | 19.67% | 19.56% | 20.35% |
Operating Margin | 1.97% | 1.87% | 1.83% | 2.78% | 2.67% | 3.36% |
Pretax Margin | 1.93% | 1.87% | 3.49% | 3.24% | 2.54% | 2.57% |
Profit Margin | 1.28% | 1.26% | 2.47% | 2.44% | 1.69% | 1.80% |
FCF Margin | 0.06% | 3.16% | -5.36% | -3.07% | 2.61% | 2.33% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 100.000 | - | - | - | 100.000 | 100.000 |
Dividend Per Share Growth | 0% | - | - | - | 0% | 0% |
Dividend Yield | 1.59% | - | - | - | 1.75% | 1.43% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.24 | 10.98 | 5.39 | 8.06 | 10.13 | 12.71 |
Forward PE | - | 14.32 | 14.32 | 14.32 | 14.32 | 14.32 |
P/FCF Ratio | 308.32 | 4.39 | - | - | 6.54 | 9.80 |
PS Ratio | 0.18 | 0.14 | 0.13 | 0.20 | 0.17 | 0.23 |